Lonza Set to Benefit From Vaxcyte's Pneumonia Vaccine

Lonza Group is expected to gain a new revenue stream from Vaxcyte's experimental pneumonia vaccine, which showed positive results in late-stage clinical trials against approved shots. RBC Capital Markets analyst Charles Weston noted this development in a research note, highlighting Lonza's embedded role in the vaccine's production.